<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04091646</url>
  </required_header>
  <id_info>
    <org_study_id>ARQ-154-203</org_study_id>
    <nct_id>NCT04091646</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis</brief_title>
  <official_title>A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects With Seborrheic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcutis Biotherapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcutis Biotherapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and effIcacy of ARQ-154 foam vs placebo applied once a day
      for 56 days by subjects with seborrheic dermatitis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a parallel group, double blind, vehicle-controlled study in which ARQ-154 foam or
      vehicle is applied once daily x 8 weeks to subjects with seborrheic dermatitis.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 4, 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator Global Assessment Scale (IGA) Score Change</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Achievement of an IGA score of 'clear' or 'almost clear' plus a 2-grade improvement from Baseline. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IGA Score Change</measure>
    <time_frame>Baseline, Week 2 and Week 4</time_frame>
    <description>Achievement of an IGA score of 'clear' or 'almost clear' plus a 2-grade improvement from Baseline at weeks 2 and 4. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Assessment of Erythema Score</measure>
    <time_frame>Baseline, Week 2, Week 4, Week 8</time_frame>
    <description>Change from Baseline in Overall Assessment of Erythema score at each study visit. Achievement of an Overall Assessment of Erythema score of 0 or 1 plus a 2-grade improvement from Baseline. This assessment scale has four severity grades reported from 0-3 and defined as None (0), Mild (1), Moderate (2), Severe (3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Assessment of Scaling Score</measure>
    <time_frame>Baseline, Week 2, Week 4, Week 8</time_frame>
    <description>Change from Baseline in Overall Assessment of Scaling score at each study visit. Achievement of an Overall Assessment of Scaling score of 0 or 1 plus a 2-grade improvement from Baseline. This assessment scale has four severity grades reported from 0-3 and defined as None (0), Mild (1), Moderate (2), Severe (3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst Itch Numeric Rating Scale (WI-NRS) Score Change</measure>
    <time_frame>Baseline, Week 2, Week 4, Week 8</time_frame>
    <description>Change in WI-NRS pruritus score from Baseline. In subjects with a Baseline WI-NRS pruritis score of &gt; 4, achievement of a &gt; 4-point improvement from Baseline. WI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from '0 to 10' (&quot;no itch&quot; to &quot;worst imaginable itch&quot;)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">226</enrollment>
  <condition>Seborrheic Dermatitis</condition>
  <arm_group>
    <arm_group_label>ARQ-154 foam 0.3%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ARQ-154 foam Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARQ-154 foam 0.3%</intervention_name>
    <description>experimental</description>
    <arm_group_label>ARQ-154 foam 0.3%</arm_group_label>
    <arm_group_label>ARQ-154 foam Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants legally competent to sign and give informed consent.

          2. Males and females ages 18 years and older (inclusive) at the time of consent.

          3. Clinical diagnosis of seborrheic dermatitis of at least 3 months duration as
             determined by the Investigator. Stable disease for the past 4 weeks.

          4. Seborrheic dermatitis of the scalp and/or face and/or trunk and/or intertriginous
             areas

          5. An Investigator Global Assessment (IGA) of disease severity of at least Moderate ('3')
             at Baseline.

          6. Overall Assessment of Erythema and Overall Assessment of Scaling scores of at least
             Moderate ('2') at Baseline.

          7. Females of childbearing potential (FOCBP) must have a negative serum pregnancy test at
             Screening (Visit 1) and a negative urine pregnancy test at Baseline (Visit 2).

          8. Females of non-childbearing potential must either be post-menopausal with spontaneous
             amenorrhea for at least 12 months or have undergone surgical sterilization.

          9. Subjects in good health as judged by the Investigator, based on medical history,
             physical examination, vital signs, serum chemistry labs, hematology values, and
             urinalysis.

         10. Subjects are considered reliable and capable of adhering to the Protocol and visit
             schedule according to the Investigator judgment.

        Exclusion Criteria:

          1. Subjects who cannot discontinue treatment with therapies for the treatment of
             seborrheic dermatitis prior to the Baseline visit and during the study according to
             Excluded Medications and Treatments

          2. Planned excessive exposure of treated area(s) to either natural or artificial
             sunlight, tanning bed or other LED

          3. Subjects who cannot discontinue the use of strong P-450 cytochrome inhibitors e.g.,
             indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole,
             nefazodone, saquinavir, suboxone and telithromycin for two weeks prior to the Baseline
             visit (Visit 2) and during the study

          4. Subjects who cannot discontinue the use of strong P-450 cytochrome inducers e.g.,
             efavirenz, nevirapine, glucocorticoids, barbiturates (including phenobarbital),
             phenytoin, rifampin, and carbamazepine for two weeks prior to the Baseline visit
             (Visit 2) and during the study.

          5. Subjects with PHQ-8 &gt;10 at Screening or Baseline visits.

          6. Previous treatment with ARQ-151 and ARQ-154.

          7. Subjects who have received oral roflumilast (Daliresp®, Daxas®) or other PDE-4
             inhibitors (apremilast) within the past 4 weeks

          8. Known allergies to excipients in ARQ-154 foam

          9. Known or suspected:

               -  severe renal insufficiency or moderate to severe hepatic disorders

               -  hypersensitivity to component(s) of the investigational products

               -  history of severe depression, suicidal ideation, or Baseline/Screening C-SSRS
                  indicative of suicidal ideation, whether lifetime or recent/current

         10. Subjects with a history of a major surgery within 8 weeks prior to Baseline (Visit 2)
             or has a major surgery planned during the study

         11. Subjects with any condition on the treatment area which, in the opinion of the
             Investigator, could confound efficacy measurements.

         12. Subjects unable to apply product to the scalp due to physical limitations.

         13. Females who are pregnant, wishing to become pregnant during the study, or are
             breast-feeding.

         14. A clinically relevant history of abuse of alcohol or other drugs, at the discretion of
             the Investigator.

         15. Subjects who are unable to communicate, read or understand the local language, or who
             display another condition, which in the Investigator's opinion, makes them unsuitable
             for clinical study participation.

         16. Subjects who are family members of the clinical study site, clinical study staff, or
             sponsor, or family members of enrolled subjects.

         17. Any condition that in the Investigator's assessment would preclude the subject from
             participating in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 19</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 21</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 42</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 24</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 12</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 10</name>
      <address>
        <city>Rolling Meadows</city>
        <state>Illinois</state>
        <zip>60008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 22</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 15</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 28</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 40</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 20</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 14</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 23</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 18</name>
      <address>
        <city>Bexley</city>
        <state>Ohio</state>
        <zip>43209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 29</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 27</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 13</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 11</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 41</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 25</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 26</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 17</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 31</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Biotherapeutics Clinical Site 30</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 13, 2019</study_first_submitted>
  <study_first_submitted_qc>September 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2019</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Seborrheic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

